Olema Oncology
Kristin Michallyszyn Brosofsky has over 20 years of experience in clinical operations within the pharmaceutical industry. Kristin has held roles such as Clinical Research Associate, Clinical Trial Manager, Sr. Clinical Trial Leader, Associate Director, and Director of Clinical Operations at companies like Antigenics, EPIX Pharmaceuticals, EMD Serono, TESARO, ImmunoGen, Surface Oncology Inc., and Olema Oncology. Their most recent position was as Senior Director of Clinical Operations at Olema Oncology.
Kristin Michallyszyn Brosofsky holds a Bachelor of Science (BSc) in microbiology from the University of Massachusetts Amherst. Kristin later pursued a Master of Public Health (MPH) degree at the University of New Hampshire.
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.